Literature DB >> 9527398

Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.

M Ots1, H S Mackenzie, J L Troy, H G Rennke, B M Brenner.   

Abstract

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (AT1RA) slow the rate of progression of experimental renal disease. Although the end result of both classes of drugs is to block the renin-angiotensin system (RAS), ACEI and AT1RA act at different sites in the RAS cascade. The aim of this study was to compare the effects of an ACEI (enalapril) and AT1RA (losartan), alone or in combination, in slowing the progression of experimental renal disease in a model of reduced renal mass. Two weeks after 5/6 renal ablation, rats were divided into five groups matched for body weight, systolic BP (SBP), and urinary protein excretion rate (UprotV). The effects on SBP and UprotV of treatment with 25 and 40 mg/L enalapril (groups I and II; both n = 7), 180 mg/L losartan (group III, n = 8), or a combination of enalapril (25 mg/L) + losartan (180 mg/L) (group IV, n = 9) versus vehicle (group V, n = 9) were studied for 12 wk. Remnant kidneys were then assessed histologically for evidence of focal and segmental glomerulosclerosis and hyalinosis (FSGS), and interstitial fibrosis. There were no significant differences (NSD) in body weight among the groups at any time. Combination therapy reduced SBP (122 +/- 8 mmHg) significantly at 12 wk to levels similar to losartan (127 +/- 3 mmHg) or enalapril (40 mg/L) alone (124 +/- 5 mmHg) (P < 0.05 versus vehicle controls). With equivalent antihypertensive effects, no differences in frequency of FSGS were discerned among the treatment groups (groups II through IV; F = 1.7, NSD). Tubulointerstitial injury scores followed a similar pattern. BP was highly correlated with the extent of FSGS, both among individual rats (r = 0.68, P = 0.05) and the group means (r = 0.99, P = 0.001). We conclude that the renoprotective effects of enalapril, losartan, or combination therapy are similar in this model over the 12 wk of the study, and are closely related to the magnitude of their antihypertensive effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527398     DOI: 10.1681/ASN.V92224

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  19 in total

Review 1.  Compelling drug indications in diabetic and nondiabetic nephropathy.

Authors:  Eberhard Ritz; Ralf Dikow; Martin Zeier
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 2.  Renal failure and ACE inhibition: how much is too much?

Authors:  M-L Gross; M Adamczak; E Ritz
Journal:  Z Kardiol       Date:  2005-02

Review 3.  Optimal strategies for preventing progression of renal disease: should angiotensin converting enzyme inhibitors and angiotensin receptor blockers be used together?

Authors:  R Komers; S Anderson
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

4.  Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System.

Authors:  Lili Zhou; Hongyan Mo; Jinhua Miao; Dong Zhou; Roderick J Tan; Fan Fan Hou; Youhua Liu
Journal:  Am J Pathol       Date:  2015-10-24       Impact factor: 4.307

5.  Effects of low protein intake on the development of the remaining kidney in subtotally nephrectomized immature rats: expression of inducible and endothelial NO synthase.

Authors:  Masaki Mino; Hideshi Ihara; Shunji Kozaki; Tomohiro Kondo; Ai Takeshita; Ken Takeshi Kusakabe; Toshiya Okada
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

6.  ASK1 contributes to fibrosis and dysfunction in models of kidney disease.

Authors:  John T Liles; Britton K Corkey; Gregory T Notte; Grant R Budas; Eric B Lansdon; Ford Hinojosa-Kirschenbaum; Shawn S Badal; Michael Lee; Brian E Schultz; Sarah Wise; Swetha Pendem; Michael Graupe; Laurie Castonguay; Keith A Koch; Melanie H Wong; Giuseppe A Papalia; Dorothy M French; Theodore Sullivan; Erik G Huntzicker; Frank Y Ma; David J Nikolic-Paterson; Tareq Altuhaifi; Haichun Yang; Agnes B Fogo; David G Breckenridge
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

Review 7.  Renoprotective therapy in patients with nondiabetic nephropathies.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

Authors:  Gaspare Parrinello; Salvatore Paterna; Daniele Torres; Pietro Di Pasquale; Manuela Mezzero; Gabriella La Rocca; Mauro Cardillo; Caterina Trapanese; Mario Caradonna; Giuseppe Licata
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Importance of blood pressure reduction for prevention of progression of renal disease.

Authors:  S C Textor; V J Canzanello
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

10.  Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.

Authors:  Urara Mori-Takeyama; Shinya Minatoguchi; Ichijirou Murata; Hisayoshi Fujiwara; Yoko Ozaki; Michiya Ohno; Hiroshi Oda; Hiroshige Ohashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.